Skip to the page

Data / Drug companies / Fresenius Kabi USA, LLC

Fresenius Kabi USA, LLC: 41 products in the FDA NDC directory, labeler code 76045

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Fresenius Kabi USA, LLC (labeler code 76045) lists 41 products in the FDA National Drug Code Directory, covering 15 finished drugs by generic name. By type: 41 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on July 28, 2026.

The request: Watch Fresenius Kabi USA, LLC (FDA labeler code 76045): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
76045
Products in commercial distribution
41
Packages
39
Finished drugs by generic name
15
Prescription products
41
Over the counter products
0
Controlled substance products
Schedule II 9, Schedule IV 5
Flagged as original packager
40 of 40 products that carry the flag
Started marketing in the last 12 months
1
Earliest marketing start
March 26, 2013
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)2663.4%
New drug applications (NDA)1536.6%

Products by type

TypeProductsShare
Prescription drugs41100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Injection, solution3790.2%
Injection24.9%
Injection, emulsion24.9%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Sugammadex76045-219Injection, solutionGeneric drugs (ANDA)July 28, 2026
Diphenhydramine Hydrochloride76045-235Injection, solutionGeneric drugs (ANDA)June 2, 2025
Naloxone Hydrochloride76045-114Injection, solutionGeneric drugs (ANDA)April 2, 2024
Naloxone Hydrochloride76045-112Injection, solutionGeneric drugs (ANDA)April 2, 2024
Dexamethasone Sodium Phosphate76045-212Injection, emulsionGeneric drugs (ANDA)February 21, 2024
Rocuronium76045-221Injection, solutionNew drug applications (NDA)October 11, 2023
Rocuronium76045-220Injection, solutionNew drug applications (NDA)October 11, 2023
Diazepam76045-204Injection, solutionGeneric drugs (ANDA)November 10, 2022
Ondansetron76045-216Injection, solutionGeneric drugs (ANDA)May 31, 2022
Glycopyrrolate76045-223InjectionNew drug applications (NDA)April 21, 2022
Glycopyrrolate76045-023InjectionNew drug applications (NDA)April 21, 2022
Midazolam76045-211Injection, solutionGeneric drugs (ANDA)April 16, 2021
Dexamethasone Sodium Phosphate76045-210Injection, solutionGeneric drugs (ANDA)November 30, 2020
Glycopyrrolate76045-208Injection, solutionGeneric drugs (ANDA)October 30, 2020
Glycopyrrolate76045-206Injection, solutionGeneric drugs (ANDA)October 30, 2020
Ketorolac Tromethamine76045-209Injection, solutionGeneric drugs (ANDA)September 1, 2020
Dilaudid76045-009Injection, solutionNew drug applications (NDA)December 4, 2018
Neostigmine Methylsulfate76045-383Injection, solutionNew drug applications (NDA)September 18, 2018
Neostigmine Methylsulfate76045-214Injection, solutionNew drug applications (NDA)September 18, 2018
Glycopyrrolate76045-203Injection, solutionGeneric drugs (ANDA)July 25, 2018
Dexamethasone Sodium Phosphate76045-109Injection, emulsionGeneric drugs (ANDA)July 6, 2018
Dilaudid76045-121Injection, solutionNew drug applications (NDA)December 16, 2016
Dilaudid76045-010Injection, solutionNew drug applications (NDA)December 16, 2016
Heparin Sodium76045-108Injection, solutionGeneric drugs (ANDA)June 10, 2016
Ondansetron76045-103Injection, solutionGeneric drugs (ANDA)December 10, 2015

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.